Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $5.3MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Huang James | Director | May 29 '26 | Buy | $2.48 | 150,000 | $371,610 | 13,310,000 | Jun 02 04:30 PM |
Company profile
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Huang James |
| Director |
| Mar 31 '26 |
| Buy |
| $3.45 |
| 1,160,000 |
| $4,002,000 |
| 13,160,000 |
| Apr 01 04:30 PM |
| Panacea Innovation Limited | 10% Owner | Nov 24 '25 | Proposed Sale | $3.00 | 2,000,000 | $6,000,000 | — | Nov 24 09:45 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.